Market Place
Sourcing Support
Judge upholds MSN`s generic Entresto nod amid Novartis challenge
19 Oct 2024 //
FIERCE PHARMA
Biocon unit gets USFDA nod for generic drug
02 Sep 2024 //
ECONOMICTIMES
Biocon`s Generics Sacubitril; Valsartan Receives Approval in US
30 Aug 2024 //
FDA
Novartis faces one win, one loss in patent cases over heart failure drug
11 Jul 2023 //
ENDPTS
Novartis will appeal to U.S. Court of Appeals to uphold validity of Entresto combination patent
07 Jul 2023 //
PRESS RELEASE
Novartis Entresto receives positive CHMP opinion for pediatric heart failure
01 Apr 2023 //
PRESS RELEASE
Sacubitril Valsartan`s USDMF has been submitted to USDMF
09 Mar 2023 //
PRESS RELEASE
HC reserves order on Natco`s plea over patent for Novartis drug
11 Jan 2023 //
ECONOMIC TIMES
JB Pharma cuts price of its top-selling heart failure drug Azmarda by 50%
06 Dec 2022 //
ECONOMICTIMES
Novartis files another Entresto patent suit to fight generics
27 Oct 2022 //
FIERCEPHARMA
Novartis hit with Entresto patent suit amid generics fight
31 Aug 2022 //
FIERCEPHARMA
Novartis income edges higher on strong Sandoz, Entresto
27 Apr 2022 //
REUTERS
Novartis petitions FDA to block 18 generic competitors for its megablockbuster
07 Dec 2021 //
ENDPTS
Novartis targets 20 blockbuster launches by 2026
03 Dec 2021 //
FIERCEPHARMA
Jardiance reduces HF outcomes and slows kidney disease decline
09 Nov 2021 //
FIERCEPHARMA
Feds probe Novartis over Entresto marketing and compensation to doctors
28 Oct 2021 //
STATNEWS
Novartis Cooperating With U.S. Probe Into Marketing of Entresto Heart Drug
28 Oct 2021 //
BLOOMBERG
DOJ probes Novartis` Entresto marketing
26 Oct 2021 //
FIERCEPHARMA
Novartis Entresto® indicated for treatment of hypertension in China
10 Jun 2021 //
PRESS RELEASE
Novartis expects sales lift from expanded heart drug approval
18 Feb 2021 //
BIOPHARMADIVE
Novartis Entresto® granted expanded indication in chronic heart failure by FDA
17 Feb 2021 //
PRNEWSWIRE
Novartis’ Entresto snags FDA nod in larger patient group
17 Feb 2021 //
FIERCE PHARMA
Novartis` bid to boost Entresto sales beyond $5 billion gets FDA panel lift
17 Dec 2020 //
REUTERS
Novartis announces positive FDA Advisory Committee for use of Entresto®
15 Dec 2020 //
PRNEWSWIRE
Study shows taking Entresto® as prescribed associated total of care by $6.7M
20 Oct 2020 //
PRNEWSWIRE
Novartis` Entresto racks up a heart failure study win—but it`s a mixed one
31 Aug 2020 //
FIERCE PHARMA
Eli Lilly, Boehringer`s Jardiance cuts CV events by 25% in heart failure trial
28 Aug 2020 //
FIERCEPHARMA
Novartis` Entresto gains steam cardiologists despiteheart failure trial flop
15 Jul 2020 //
FIERCEPHARMAR
Otsuka enters into co-promotion agreement for angiotensin ARNI LCZ696 in Japan
02 Mar 2020 //
PREE RELEASE
Once again Novartis’ cardio team looks to beat the odds using sketchy data
03 Sep 2019 //
ENDPTS
Once again Novartis’ cardio team looks to beat the odds using sketchy data
03 Sep 2019 //
ENDPTS
Novartis aims for 10 blockbuster launches by 2020
30 Jan 2019 //
PMLIVE
Novartis expects a parade to blockbusterland, with Entresto leading the way
30 Jan 2019 //
FIERCE PHARMA
Novartis` Entresto tops enalapril in stabilised heart failure patients
13 Nov 2018 //
PHARMA FILE
New Novartis study supports Entresto as HFrEF therapy in Heart failure
11 Nov 2018 //
PR NEWSWIRE
Tainted valsartan has been on the market for 4 years: FDA
07 Aug 2018 //
FIERCE PHARMA
Authorised products containing valsartan as active substance: Overview
16 Jul 2018 //
SWISSMEDIC
Novartis` Entresto helps preserve kidney function in chronic heart failur
16 Apr 2018 //
PHARMAFILE
Renewed interest in ‘understudied’ co-crystals as better meds, say scientist
12 Mar 2018 //
IN PHARMATECHNOLOGIST
Novartis finally gains market traction with heart drug Entresto
16 Aug 2017 //
FIERCE PHARMA
When `New and Improved` Fails: Insulin Maker -2-
15 Aug 2017 //
WALL STREET JOURNAL
CV data sets up Novartis` Ilaris for blockbuster sales
23 Jun 2017 //
PMLIVE
New drugs can`t keep Novartis sales on the up
26 Apr 2017 //
PMLIVE
